Study details
Enrolling now
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
NCT IDNCT05093335ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
30
Study length
about 5.1 years
Ages
18+
Locations
1 site in NY
About this study
Researchers are testing a treatment called [68Ga]-Pentixafor to see how well it shows up in the body using PET/CT scans. The trial will involve people with conditions like Erdheim-Chester Disease, Histiocytic Neoplasms, Lymphoma, Multiple Myeloma, and Rosai-Dorfman Disease.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [68Ga]-Pentixafor
PhaseEARLY_Phase 1
Primary goalTumor standard uptake value (SUV)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Tumor standard uptake value (SUV)
Body systems
Oncology